|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's range||42.65 - 44.51|
|52-week range||29.50 - 78.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||72.33|
They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.
The stock market got off to a mixed start on Monday, but that wasn't evident to investors in the Nasdaq Composite (NASDAQINDEX: ^IXIC). As it often has before, the Nasdaq pushed higher even as other major market benchmarks fell, with gains of about two-thirds of a percent as of 11:30 a.m. EDT. Plenty of the Nasdaq's biggest stocks were among the gainers to start the new week.
CAMBRIDGE, Mass., Jun 17, 2021--Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of its initial public offering of 14,035,789 shares of its common stock at a price to the public of $19.00 per share. The gross proceeds to Verve from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $266.7 million. All of the s